The grant, stated plainly. On September 10, 2024, Arcturus Therapeutics was issued US12083224B2, covering lipid particles for nucleic acid delivery. The CPC tags — A61K 9/1272 (lipid-particle preparation), A61K 31/7105 and 31/711 (RNA actives), A61K 39/12 (viral antigens) — describe a delivery system for nucleic-acid payloads including next-generation constructs.
Why an event-driven desk notes delivery IP: in mRNA medicine, the delivery vehicle determines what payloads are feasible — including larger, self-amplifying constructs that promise lower doses. Delivery IP is the gate; programs that own or license differentiated delivery are the ones whose clinical readouts become meaningful catalysts.
The disciplined read: a lipid-particle delivery grant is an exclusivity claim on a delivery system, not a clinical result. The catalyst value rides on whether the delivery enables the payload to perform in patients — answered by data, not the patent.
What the grant does not say: nothing about a specific readout, efficacy, safety, or freedom from competing LNP estates. Those are separate facts in separate records.
The takeaway: when tracking next-generation mRNA programs, read the delivery grants to see which sponsors have a differentiated vehicle, then follow the readouts. Arcturus' September 2024 lipid-particle grant is a dated marker in that delivery race.